drugset / Trial / NCT04339504

Follow-up Safety and Efficacy Evaluation on Subjects Who Completed Phase I Clinical Trial

NCT04339504

Phase 1 Unknown 12 enrolled Medipost Co Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a follow-up study to investigate the long-term safety and explore efficacy of SMUP-IA-01, for the treatment of Knee Osteoarthritis. Subjects who participated in and completed the initial stage of the Phase I trial (NCT04037345 ) will be followed-up until 60 months.

Timeline

Start
2020-04-14
Primary completion
2025-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SMUP-IA-01 Cell therapy 4e+06 cells Other
Subject SMUP-IA-01 Cell therapy 1e+07 cells Other
Subject SMUP-IA-01 Cell therapy 2e+07 cells Other

Indications